Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020;58(4):221-230.
doi: 10.5114/reum.2020.98434. Epub 2020 Aug 31.

Impact of IL-34, IFN-α and IFN-λ1 on activity of systemic lupus erythematosus in Egyptian patients

Affiliations

Impact of IL-34, IFN-α and IFN-λ1 on activity of systemic lupus erythematosus in Egyptian patients

Yasmin Adel et al. Reumatologia. 2020.

Abstract

Background: Systemic lupus erythematosus (SLE) is an autoimmune, multi-system inflammatory disease. Among cytokines involved in SLE pathogenesis, interferons (particularly IFN-α) and interleukin 34 play a pivotal role. Interestingly, the gene signatures of type III (IFN-λ1) and type I IFNs may overlap. Increased levels of IFN-λ also have been reported in SLE.Objectives: The aim of this study was to assess serum levels of IL-34, IFN-λ1, IFN-α and the relationship between these cytokines and clinical and laboratory parameters and response to treatment in a cohort of Egyptian SLE patients.

Material and methods: The study included 82 newly diagnosed SLE patients: male 17.1% (n = 14), female 82.9% (n = 68), mean age ±SD: 48.6 ±8.2 and 60 healthy subjects matched by age and gender as a control group. Medical history, physical examination and laboratory tests for confirming SLE diagnosis and assessment of disease activity were collected. The assessment of serum levels of studied cytokines were performed using the ELISA method.All studied patients after first cytokine evaluation were treated with a combination of antimalarial drugs, glucocorticosteroids and/or immunosuppressive drugs with follow-up after six months of treatment.

Results: In the SLE group the mean serum levels of IL-34, IFN-α and IFN-λ1 were 175.9 ±125.9 pg/ml, 109.3 ±32.5 pg/ml and 227.9 ±144.8 pg/ml respectively. These cytokine levels were significantly higher in the SLE group than in healthy controls. 39% of SLE patients (n = 32) had SLAM > 6 and 26.8% (n = 22) had SLEDAI >6. There were 21 SLE patients (25.6%) with lupus nephritis.IL-34 and IFN-λ1 were positively correlated with anti-dsDNA antibodies but negatively correlated with C3 complement component (p ≤ 0.05). IL-34, INF-α and IFN-λ1 were significantly higher in lupus nephritis patients, and correlated with poorest response to treatment.IL-34 and IFN-λ1 were correlated with higher SLAM > 6 and SLEDAI > 6 results; there was no such correlation between IFN-α and disease activity.Accumulation of three or more clinical features during follow-up was significantly associated with high levels of studied cytokines. Triple high positivity was found in 17 patients (20.7%) and correlated with presence of anti-dsDNA antibodies, low levels of C3 component of complement and lupus nephritis.

Conclusions: SLE patients with high serum levels of IL-34, IFN-α and IFN-λ1 more often had lupus nephritis and poor response to immunosuppressive treatment.The triple cytokine elevation was strongly associated with higher disease activity. These results may indicate the need to distinguish this group of patients with such aggressive phenotype and consider targeted multi-therapy.

Keywords: disease activity; interferon; interleukin; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1A.
Fig. 1A.
Correlations of serum IL-34 with studied parameters
Fig. 1B.
Fig. 1B.
Correlations of serum IFN-α with studied parameters.
Fig. 1C.
Fig. 1C.
Correlations of serum IFN-λ1 with studied parameters.
Fig. 2
Fig. 2
Graphic presentation of IL-34, IFN-α and IFN-λ1 serum levels and correlations with lupus nephritis (LN), SLAM, SLEDAI and response to treatment.

References

    1. Nakamichi Y, Udagawa N, Takahashi N. IL-34 and CSF-1: similarities and differences. J Bone Miner Metab 2013; 31: 486-495, DOI: 10.1007/s00774-013-0476-3. - DOI - PubMed
    1. Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014; 384: 1878-1888, DOI: 10.1016/S0140-6736(14)60128-8. - DOI - PubMed
    1. Chen Z, Kalman Buki K, Vääräniemi J, et al. The critical role of IL-34 in osteoclastogenesis. PLoS One 2011; 6: e18689, DOI: 10.1371/journal.pone.0018689. - DOI - PMC - PubMed
    1. Zhou RP, Wu XS, Xie YY, et al. Functions of interleukin-34 and its emerging association with rheumatoid arthritis. Immunology 2016; 149: 362-373, DOI: 10.1111/imm.12660. - DOI - PMC - PubMed
    1. Masteller EL, Wong BR. Targeting IL-34 in chronic inflammation. Drug Discov Today 2014; 19: 1212-1216, DOI: 10.1016/j.drudis.2014.05.016. - DOI - PubMed